RheumNow Podcast – Late Breaking Abstract Wrap-Up (6.21.19) Save
Dr. Jack Cush reviews the week’s news and wrap up from EULAR19.
- FORWARD, a National Databank study, looked at malignancies & infections in RA pts starting abatacept, other biologicsor DMARDs. No difference in cancer risks, but ABA had lower risk hospitalized infx (HR 0.37) & lower infusion/injx rxn than other biologics https://t.co/9GonhVTK3Z
- ethotrexate assoc. lymphoproliferative disorders (LPDs), is a rare disorder that resolves w/ MTX withdrawal (in 3-10mos). Most common path was diffuse large B-cell lymphoma and 45-77% had Epstein-Barr virus encoded RNA positivity. https://t.co/xF8YLiI2lc
- #EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/5K58IUNdCV
- A survey of 900 Danish rheumatic dz pts shows that 1 in 10 with pain have considered suicide in the last 4 weeks and that this was strongly influenced by poor quality sleep. #EULAR2019 OP0347 https://t.co/hfIWXEC4Xo
- No Difference Among Biologics in Arthroplasty Infectious Risk
- Allopurinol Fails to Curtail Hypertension
- Is Methotrexate Necessary with Tofacitinib
- EULAR 2019- Day 4 Report
- SPIRIT-H2H trial in PsA: LB005
- Early AMPLE study LB008
- Vagal Nerve Stimulation in RA: LB009
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.